271 days without a machine. Then Tim Andrews got a human kidney.
In January 2025, surgeons at Massachusetts General Hospital gave Andrews a kidney from a pig. The organ had been stripped of its most dangerous viral genes and laced with human DNA to stop his immune system from attacking it. For 271 days, it worked. No machine filtered his blood. No three-times-a-week sessions tethered him to a clinic. Then, in early 2026, doctors removed the pig kidney. Eighty-two days later, Andrews received a human donor kidney. He is alive, and the pig organ did not sensitize his body against the human one that followed.
That sequence of events, published in The Lancet by Mass General Brigham researchers, is not just a medical curiosity. It is the first clinical proof that a genetically engineered pig kidney can serve as a bridge, keeping a patient alive and transplant-eligible until a human organ becomes available. The old fear that a xenograft would permanently bar a patient from ever receiving a human kidney turns out to be wrong.
Five Patients, One Record
The Andrews case is part of a broader clinical update from eGenesis, the Cambridge-based biotech behind the EGEN-2784 pig kidney. According to an eGenesis press release on September 3, 2026, the company has now transplanted five patients with kidney failure under the FDA’s Expanded Access pathway since March 2024. Three of those patients have sustained kidney function for more than eight months without dialysis. One has surpassed nine months of dialysis independence, a new global record for a genetically engineered porcine kidney transplant. That patient remains on study.
Two of the five have transitioned to human donor kidneys. These are the first reported cases of a patient moving from xenotransplantation to allotransplantation, or human-to-human transplant. The data is slim but it is real, and it rewrites the operating assumptions about what pig kidneys can do.
The 69 Edits and a Brutal Arithmetic
The numbers behind this moment are stark. More than 800,000 Americans live with end-stage kidney disease. In 2024, only 28,000 kidney transplants were performed in the United States. The rest wait on dialysis, where the five-year mortality rate is 60 percent. The organ shortage, as Leonardo Riella of Mass General Brigham puts it, is “the greatest crisis we have right now in transplantation.”
eGenesis’s approach is to build an organ that the human immune system will tolerate. The EGEN-2784 kidney comes from a pig with 69 genomic edits. Scientists knocked out three major carbohydrate antigens that trigger hyperacute rejection, inserted seven human transgenes to regulate coagulation, inflammation, and immune response, and inactivated porcine endogenous retroviruses (PERVs) embedded in the pig genome. The edits are designed to make the organ invisible enough to buy time.
Time is the scarce resource. The first living human to receive a porcine kidney xenotransplant, a 62-year-old man treated at Mass General in 2024, survived 52 days before dying from sudden cardiac causes. An autopsy showed severe coronary artery disease. The kidney itself showed no signs of rejection. That case, published in the New England Journal of Medicine, established that the 69-edit organ could function without immediate immune destruction. It also showed that the patients who are sick enough to qualify for these early procedures bring lethal comorbidities with them.
Why the Bridge Matters More Than the Record
The nine-month survival record is a headline. The bridge concept is the strategy that matters.
Andrews lived with his pig kidney for 271 days, then had it removed. He waited 82 days, then received a human kidney. If the xenograft had sensitized his immune system, if it had produced antibodies that would attack a subsequent human organ, that transplant would have failed or never been attempted. It did not. The pig kidney acted as a true bridge, and the human kidney followed.
This changes the clinical calculus. Xenotransplantation has been framed as a destination: a permanent replacement organ for patients who will never get a human one. That framing forced the technology to clear an impossibly high bar. A permanent xenograft must match the durability of a human kidney, avoid chronic rejection for years, and manage infection risk over decades. A bridge does not need any of that. It needs to function for six to twelve months, keep a patient off dialysis, and then exit without closing the door to a human organ.
eGenesis CEO Mike Curtis frames the goal as making transplantation available “when patients need it, without being constrained by the limited supply of human donor organs.” The bridge strategy is the most realistic path to that goal right now.
The Safety Event That Will Delay RESTORE
Here is what comes next, and it is not as clean as the press release suggests.
The five Expanded Access patients are highly selected and intensively monitored. They received the pig kidney under a compassionate-use framework that allows for bespoke immunosuppression regimens and round-the-clock surveillance. The RESTORE trial, the Phase 1/2/3 study that the FDA has cleared eGenesis to begin, is expected to start in the first quarter of 2027. It will enroll a broader population under standardized protocols.
In the next 12 to 24 months, at least one of the Expanded Access patients will likely die from xenograft rejection or an infection tied to the immunosuppression required to maintain the organ. The mechanism is predictable. Chronic antibody-mediated rejection is a slow, stealthy killer in human kidney transplantation. A pig kidney with 69 edits is still foreign. Over months, the recipient’s immune system will generate donor-specific antibodies against porcine antigens that the edits did not remove. The organ will scar, its function will decline, and the patient will either lose the graft or die from the consequences.
Infection is the other vector. A latent porcine endogenous retrovirus could reactivate in an immunosuppressed host. The edits inactivate PERVs in the pig genome, but no editing process is perfectly efficient in every cell. A single reactivation event in the wrong patient could be catastrophic.
The FDA will review those safety events. The agency will have questions about patient selection, about immunosuppression protocols, about monitoring for zoonotic infection. It will likely demand modifications to the RESTORE trial design, possibly including longer preclinical data requirements, additional viral surveillance, or a narrower enrollment window. The trial’s start will slip from early 2027 into late 2027 or early 2028.
The second-order effect will be a reset of the hype cycle. The early narrative around xenotransplantation has been triumphalist. A patient death tied directly to the graft will puncture that. The stock prices of the small number of public companies in the space will fall. The breathless coverage will turn skeptical. But the underlying science will survive because the bridge data is real and the unmet need is too large to ignore.
The third-order effect is that the bridge strategy will become the dominant clinical and regulatory path, not the permanent xenograft. Companies that can prove a pig kidney safely holds a patient for 6 to 12 months will find a faster route to approval than those promising a lifetime cure. The FDA will be more comfortable with a temporary organ that buys time on the transplant list than with a permanent one that must compete with human kidneys on durability.
Bet on the Bridge, Not the Destination
For the operator, whether a biotech investor, a transplant surgeon, or a policymaker, the takeaway is clear. The short-term capital and regulatory attention will flow to bridge applications. A company that can demonstrate a clean transition from pig kidney to human kidney, as eGenesis has now done twice, owns the most valuable clinical narrative in the field.
The path for a permanent xenograft just got longer. The safety data that will emerge from Expanded Access patients over the next two years will raise the evidentiary bar, not lower it. The path for a temporary bridge just got shorter. The Andrews case proves the concept works. The regulatory question is now about how to standardize it, not whether to allow it.
For the 800,000 Americans on the list, that distinction is everything. A bridge is not a cure. It is a way to stay alive long enough to get one.
A Bridge, Not a Cure
Tim Andrews did not get a permanent fix from a pig. He got 271 days without dialysis, then a human kidney. Those 271 days bought him time that the waiting list might never have given him.
That is the real promise of the eGenesis pig kidney in 2026: not a destination, but a bridge. The records will fall. The safety events will come. The trials will be delayed. And underneath all of that noise, the fundamental fact will hold: a genetically engineered pig kidney can keep a human being alive and transplant-eligible long enough for a human organ to arrive. That alone is enough to change the arithmetic of the organ shortage.
The question is no longer whether xenotransplantation works. It is how to build the system around the bridge, before the next safety event forces everyone to slow down.
